Drugs / Clostridium butyricum CBM 588 Probiotic Strain
Clostridium butyricum CBM 588 Probiotic Strain
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03829111 | May 2019 → Dec 2023 | clear cell renal carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03922035 | Apr 2019 → Feb 2027 expected | hematopoietic and lymphoid cell neoplasm | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07383441 | Jun 2026 → Jan 2033 expected | clear cell renal carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium butyricum CBM 588 Probiotic Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03829111 ↗ |
| Known as | C. butyricum CBM 588 Probiotic Strain | “C. butyricum CBM 588 Probiotic Strain” NCT03922035 ↗ |
| Known as | CBM588 | “CBM588” NCT03922035 ↗ |
| Known as | MO-03 | “To compare investigator assessed progression-free survival of participants with advanced clear cell renal cell carcinoma (ccRCC) randomized to standard of care immunotherapy...” NCT07383441 ↗ |
| Modality | Other / unclassified | “CBM588 is a bifidogenic live bacterial product” PMID 35228755 ↗ Feb 2022 |
| Route | Oral | “Given PO” NCT03829111 ↗ |